VYLEESI is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women who have not gone through menopause, who have not had problems with low sexual desire in the ...
Partnership will increase hypoactive sexual desire disorder (HSDD) awareness and expand access to Vyleesi via UpScriptHealth's Women's Health Platform CRANBURY, N.J., Aug. 7, 2023 /PRNewswire/ -- ...
CRANBURY, N.J., July 26, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Valeant, now Bausch Health, paid $1 billon in 2015 for Sprout Pharmaceuticals’ female libido drug Addyi, only to sell it back in 2017. Now as the drug is still nowhere near the blockbuster status ...
CRANBURY, N.J., Feb. 28, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the ...
Vyleesi is approved for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes markeddistress or ...
CRANBURY, N.J., May 4, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
The U.S. Food and Drug Administration today approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. “There are women who, for ...
Vyleesi (bremelanotide injection; AMAG Pharmaceuticals) is now commercially available through specialty pharmacies, Avella and BioPlus. Vyleesi (bremelanotide injection; AMAG Pharmaceuticals) is now ...
Partnership will increase hypoactive sexual desire disorder (HSDD) awareness and expand access to Vyleesi via UpScriptHealth's Women's Health Platform "We are excited to partner with UpScriptHealth, a ...
The U.S. Food and Drug Administration today approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. “There are women who, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback